CUV 1.61% $14.68 clinuvel pharmaceuticals limited

Still Undervalued, page-22

  1. 1,195 Posts.
    lightbulb Created with Sketch. 1
    dont get me wrong... i really enjoy the CUV story and I am not selling... but I am annoyed that the price jumped possibly unwarranted. I would really like some non financial metrics.

    A big difference with SRX is that is is one of many possible treatments available to a much larger population... where as CUV is the only treatment although targeted at a much smaller audience.

    I would like to be still owning CUV shares in 3 to 5 years time... but I suspect they would be taken over before then.

    cuv101... it did cross my mind that SRX is possibly too cheap when i did this analysis... but i havent looked at it closely for about 2 years...
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.